Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 4/2007

01.04.2007 | Original article

Quantification of Parkinson’s disease-related network expression with ECD SPECT

verfasst von: Thomas Eckert, Koen Van Laere, Chengke Tang, Daniel E. Lewis, Christine Edwards, Patrick Santens, David Eidelberg

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Spatial covariance analysis has been used with FDG PET to identify a specific metabolic network associated with Parkinson’s disease (PD). In the current study, we utilized a new, fully automated voxel-based method to quantify network expression in ECD SPECT images from patients with classical PD, patients with multiple system atrophy (MSA), and healthy control subjects.

Methods

We applied a previously validated voxel-based PD-related covariance pattern (PDRP) to quantify network expression in the ECD SPECT scans of 35 PD patients, 15 age- and disease severity-matched MSA patients, and 35 age-matched healthy control subjects. PDRP scores were compared across groups using analysis of variance. The sensitivity and specificity of the prospectively computed PDRP scores in the differential diagnosis of individual subjects were assessed by receiver operating characteristic (ROC) analysis.

Results

PDRP scores were significantly increased (p < 0.001) in the PD group relative to the MSA and control groups. ROC analysis indicated that the overall diagnostic accuracy of the PDRP measures was 0.91 (AUC). The optimal cutoff value was consistent with a sensitivity of 0.97 and a specificity of 0.80 and 0.71 for discriminating PD patients from MSA and normal controls, respectively.

Conclusion

Our findings suggest that fully automated voxel-based network assessment techniques can be used to quantify network expression in the ECD SPECT scans of parkinsonian patients.
Literatur
1.
Zurück zum Zitat Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044–53.PubMedCrossRef Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044–53.PubMedCrossRef
2.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–9.PubMedCrossRef Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–9.PubMedCrossRef
3.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.PubMedCrossRef Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.PubMedCrossRef
4.
Zurück zum Zitat Vanacore N. Epidemiological evidence on multiple system atrophy. J Neural Transm 2005;112:1605–12.PubMedCrossRef Vanacore N. Epidemiological evidence on multiple system atrophy. J Neural Transm 2005;112:1605–12.PubMedCrossRef
5.
Zurück zum Zitat Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson’s disease and multiple system atrophy. Clin Auton Res 2004;14:84–91.PubMedCrossRef Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson’s disease and multiple system atrophy. Clin Auton Res 2004;14:84–91.PubMedCrossRef
6.
Zurück zum Zitat Eckert T, Sailer M, Kaufmann J, Schrader C, Peschel T, Bodammer N, et al. Differentiation of idiopathic Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21:229–35.PubMedCrossRef Eckert T, Sailer M, Kaufmann J, Schrader C, Peschel T, Bodammer N, et al. Differentiation of idiopathic Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21:229–35.PubMedCrossRef
7.
Zurück zum Zitat Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697–702.PubMed Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697–702.PubMed
8.
Zurück zum Zitat Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922–7.PubMedCrossRef Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922–7.PubMedCrossRef
9.
Zurück zum Zitat Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierckx R. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson’s disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 2004;45:933–42.PubMed Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierckx R. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson’s disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 2004;45:933–42.PubMed
10.
Zurück zum Zitat Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21.PubMedCrossRef Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21.PubMedCrossRef
11.
Zurück zum Zitat Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. Neurorx 2005;2:361–71.PubMedCrossRef Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. Neurorx 2005;2:361–71.PubMedCrossRef
12.
Zurück zum Zitat Ma Y, Tang C, Spetsieres P, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility. J Cereb Blood Flow Metab 2006; in press. Ma Y, Tang C, Spetsieres P, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility. J Cereb Blood Flow Metab 2006; in press.
13.
Zurück zum Zitat Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40:1264–9.PubMed Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40:1264–9.PubMed
14.
Zurück zum Zitat Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson’s disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236–45.PubMedCrossRef Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson’s disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236–45.PubMedCrossRef
15.
Zurück zum Zitat Asanuma K, Ma Y, Huang C, Carbon-Correll M, Edwards C, Raymond D, et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol 2005;57:596–600.PubMedCrossRef Asanuma K, Ma Y, Huang C, Carbon-Correll M, Edwards C, Raymond D, et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol 2005;57:596–600.PubMedCrossRef
16.
Zurück zum Zitat Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology 2001;57:2083–8.PubMed Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology 2001;57:2083–8.PubMed
17.
Zurück zum Zitat Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, et al. Network modulation in the treatment of Parkinson’s disease. Brain 2006;129:2667–78.PubMedCrossRef Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, et al. Network modulation in the treatment of Parkinson’s disease. Brain 2006;129:2667–78.PubMedCrossRef
18.
Zurück zum Zitat Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism. Brain 2001;124:1601–9.PubMedCrossRef Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism. Brain 2001;124:1601–9.PubMedCrossRef
19.
Zurück zum Zitat Trošt M, Su S, Su P, Yen RF, Tseng HM, Barnes A, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease. Neuroimage 2006;31:301–7.PubMedCrossRef Trošt M, Su S, Su P, Yen RF, Tseng HM, Barnes A, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease. Neuroimage 2006;31:301–7.PubMedCrossRef
20.
Zurück zum Zitat Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002;17:1265–70.PubMedCrossRef Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002;17:1265–70.PubMedCrossRef
21.
Zurück zum Zitat Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42.PubMedCrossRef Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42.PubMedCrossRef
22.
Zurück zum Zitat Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835–45.PubMedCrossRef Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835–45.PubMedCrossRef
23.
Zurück zum Zitat Van Laere K, Koole M, Versijpt J, Vandenberghe S, Brans B, D’sAsseler Y, et al. Transfer of normal 99mTc-ECD brain SPET databases between different gamma cameras. Eur J Nucl Med 2001;28:435–49.PubMedCrossRef Van Laere K, Koole M, Versijpt J, Vandenberghe S, Brans B, D’sAsseler Y, et al. Transfer of normal 99mTc-ECD brain SPET databases between different gamma cameras. Eur J Nucl Med 2001;28:435–49.PubMedCrossRef
24.
Zurück zum Zitat Spetsieris P, Ma Y, Dhawan V, Moeller J, Eidelberg D. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: Medical Imaging 2006;6144:61445M1–12. Spetsieris P, Ma Y, Dhawan V, Moeller J, Eidelberg D. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: Medical Imaging 2006;6144:61445M1–12.
25.
Zurück zum Zitat Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998;25:1032–7.PubMed Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998;25:1032–7.PubMed
26.
Zurück zum Zitat Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003;229:3–8.PubMed Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003;229:3–8.PubMed
27.
Zurück zum Zitat Huang C, Feigin A, Ma Y, Eidelberg D. Imaging measures of longitudinal change in Parkinson’s disease. Neurology 2005;64(6, Suppl 1):A325. Huang C, Feigin A, Ma Y, Eidelberg D. Imaging measures of longitudinal change in Parkinson’s disease. Neurology 2005;64(6, Suppl 1):A325.
28.
Zurück zum Zitat Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson’s disease and normal ageing. Brain 1997;120:2197–206.PubMedCrossRef Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson’s disease and normal ageing. Brain 1997;120:2197–206.PubMedCrossRef
29.
Zurück zum Zitat Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 1995;36:378–83.PubMed Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 1995;36:378–83.PubMed
30.
Zurück zum Zitat Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783–801.PubMed Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783–801.PubMed
31.
Zurück zum Zitat Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Early differential diagnosis of Parkinson’s disease with18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995–2004.PubMed Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Early differential diagnosis of Parkinson’s disease with18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995–2004.PubMed
32.
Zurück zum Zitat Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93–100.PubMedCrossRef Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93–100.PubMedCrossRef
33.
Zurück zum Zitat Kobari M, Fukuuchi Y, Shinohara T, Obara K, Nogawa S. Levodopa-induced local cerebral blood flow changes in Parkinson’s disease and related disorders. J Neurol Sci 1995;128:212–8.PubMedCrossRef Kobari M, Fukuuchi Y, Shinohara T, Obara K, Nogawa S. Levodopa-induced local cerebral blood flow changes in Parkinson’s disease and related disorders. J Neurol Sci 1995;128:212–8.PubMedCrossRef
34.
Zurück zum Zitat Ma Y, Eckert T, Feigin A, Dhawan V, Eidelberg D. Abnormal metabolic topography in patients with multiple systems atrophy: a FDG PET study. Neurology 2005;64(6, suppl 1):A235. Ma Y, Eckert T, Feigin A, Dhawan V, Eidelberg D. Abnormal metabolic topography in patients with multiple systems atrophy: a FDG PET study. Neurology 2005;64(6, suppl 1):A235.
35.
Zurück zum Zitat Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease. Ann Neurol 1993;33:518–27.PubMedCrossRef Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease. Ann Neurol 1993;33:518–27.PubMedCrossRef
Metadaten
Titel
Quantification of Parkinson’s disease-related network expression with ECD SPECT
verfasst von
Thomas Eckert
Koen Van Laere
Chengke Tang
Daniel E. Lewis
Christine Edwards
Patrick Santens
David Eidelberg
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0261-9

Weitere Artikel der Ausgabe 4/2007

European Journal of Nuclear Medicine and Molecular Imaging 4/2007 Zur Ausgabe